MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers, Tumor
Female
Fusion Proteins, bcr-abl
/ genetics
Humans
Kaplan-Meier Estimate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ diagnosis
Male
Middle Aged
Prognosis
Protein Kinase Inhibitors
/ administration & dosage
Real-Time Polymerase Chain Reaction
/ methods
Transcription, Genetic
Young Adult
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
16
12
2018
accepted:
21
03
2019
pubmed:
30
3
2019
medline:
14
7
2020
entrez:
30
3
2019
Statut:
ppublish
Résumé
The majority of patients with newly diagnosed chronic myeloid leukemia (CML) will enjoy a life expectancy equivalent to that of unaffected individuals, but will remain on life-long treatment with a concomitant requirement for on-going hospital interactions for molecular monitoring and drug dispensing. In order to determine more accurately the frequency of monitoring required, we performed a 'real-life' retrospective single-center cohort study of 450 patients with CML in at least major molecular remission (MR3) to analyze the risk of loss of MR3 [defined as at least 2 consecutive real-time quantitative polymerase chain reaction (RT-qPCR) results >0.1% International Scale (IS)]. Patients who achieved sustained MR4 (sMR4, BCR-ABL1 RT-qPCR <0.01% IS for 12 months) had a probability of loss of MR3 at 1 and 5 years of 0 and 2.6% (95%CI: 1.2-5.4) respectively, compared to 4.4% (95%CI: 1.9-9.8) and 25.4% (95%CI: 16.7-36.7) respectively, in those who achieved sustained MR3 (sMR3) but not sMR4 (
Identifiants
pubmed: 30923102
pii: haematol.2018.214809
doi: 10.3324/haematol.2018.214809
pmc: PMC6821602
doi:
Substances chimiques
Biomarkers, Tumor
0
Protein Kinase Inhibitors
0
Fusion Proteins, bcr-abl
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2206-2214Informations de copyright
Copyright© 2019 Ferrata Storti Foundation.
Références
J Clin Oncol. 2009 Aug 1;27(22):3659-63
pubmed: 19487383
Blood. 2013 May 9;121(19):3818-24
pubmed: 23515925
Hematology Am Soc Hematol Educ Program. 2007;:376-83
pubmed: 18024654
Blood. 2017 Feb 16;129(7):846-854
pubmed: 27932374
Cancer. 2008 Feb 15;112(4):837-45
pubmed: 18085610
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Hematology Am Soc Hematol Educ Program. 2009;:477-87
pubmed: 20008233
J Clin Oncol. 2014 Feb 10;32(5):415-23
pubmed: 24297946
Blood. 2014 Feb 27;123(9):1353-60
pubmed: 24335106
J Clin Oncol. 2017 Jan 20;35(3):298-305
pubmed: 28095277
Clin Cancer Res. 2007 Oct 15;13(20):6136-43
pubmed: 17947479
Clin Cancer Res. 2006 May 15;12(10):3037-42
pubmed: 16707599
J Clin Oncol. 2012 Jan 20;30(3):232-8
pubmed: 22067393
N Engl J Med. 2017 Mar 9;376(10):917-927
pubmed: 28273028
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Blood. 2008 Dec 1;112(12):4437-44
pubmed: 18716134
J Clin Oncol. 2016 Aug 20;34(24):2851-7
pubmed: 27325849
Haematologica. 2017 Aug;102(8):e297-e299
pubmed: 28495914
Blood. 2006 Jun 1;107(11):4250-6
pubmed: 16467199
Blood. 2013 Jun 13;121(24):4867-74
pubmed: 23620574
CA Cancer J Clin. 2018 Mar;68(2):153-165
pubmed: 29338071
Leukemia. 2016 May;30(5):1044-54
pubmed: 26837842
Lancet Haematol. 2017 Jul;4(7):e310-e316
pubmed: 28566209
J Clin Oncol. 2016 Jul 10;34(20):2333-40
pubmed: 27217448
Leukemia. 2017 Nov;31(11):2398-2406
pubmed: 28804124
Br J Haematol. 2011 Apr;153(2):179-90
pubmed: 21382019
Leukemia. 2012 Sep;26(9):2096-102
pubmed: 22446502
J Natl Compr Canc Netw. 2018 Sep;16(9):1108-1135
pubmed: 30181422
Lancet Oncol. 2018 Jun;19(6):747-757
pubmed: 29735299
J Clin Oncol. 2010 May 10;28(14):2381-8
pubmed: 20385986
Clin Cancer Res. 2009 Feb 1;15(3):1059-63
pubmed: 19188180